Target engagement and drug residence time can be observed in living cells with BRET

Nature Communications

Volumn 6, Issue , 2015, Pages

  Robers, Matthew B ^a   Dart, Melanie L ^a   Woodroofe, Carolyn C ^b,d   Zimprich, Chad A ^a   Kirkland, Thomas A ^b   Machleidt, Thomas ^a   Kupcho, Kevin R ^a   Levin, Sergiy ^b   Hartnett, James R ^a   Zimmerman, Kristopher ^a   Niles, Andrew L ^a   Ohana, Rachel Friedman ^a   Daniels, Danette L ^a   Slater, Michael ^a   Wood, Monika G ^a   Cong, Mei ^a   Cheng, Yi Qiang ^c   Wood, Keith V ^a  

^a PROMEGA CORPORATION   (United States)

^b Promega Biosciences Inc   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; LUCIFERASE; PANOBINOSTAT; RICOLINOSTAT; ROMIDEPSIN; TRICHOSTATIN A; VORINOSTAT; DRUG; HISTONE DEACETYLASE INHIBITOR;

BIOLUMINESCENCE; CELLS AND CELL COMPONENTS; DRUG; ENERGY FLOW; ENZYME ACTIVITY; PROTEIN; REACTION KINETICS; RESIDENCE TIME; RESONANCE; TRACER;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING KINETICS; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; EMBRYO; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; IC50; LIMIT OF DETECTION; MEAN RESIDENCE TIME; MEMBRANE PERMEABILITY; MICROENVIRONMENT; MOLECULAR INTERACTION; PROTEIN EXPRESSION; PROTEIN TARGETING; CELLS; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; EVALUATION STUDY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETICS; LUMINESCENCE; METABOLISM; PROCEDURES;

CELL PROLIFERATION; CELLS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HELA CELLS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HUMANS; LUCIFERASES; LUMINESCENCE; PHARMACEUTICAL PREPARATIONS;

EID: 84949294621     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10091     Document Type: Article

References (56)

1. Copeland, R. A., Pompliano, D. L. & Meek, T. D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug. Discov. 5, 730-739 (2006).
2. Lu, H. & Tonge, P. J. Drug-target residence time: critical information for lead optimization. Curr. Opin. Chem. Biol. 14, 467-474 (2010).
3. Tummino, P. J. & Copeland, R. A. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47, 5481-5492 (2008).
4. Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255-265 (2011).
5. Becher, I. et al. Chemoproteomics reveals time-dependent binding of histone deacetylase inhibitors to endogenous repressor complexes. ACS Chem. Biol. 9, 1736-1746 (2014).
6. Vauquelin, G. & Charlton, S. J. Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. Br. J. Pharmacol. 168, 1771-1785 (2013).
7. Vauquelin, G. Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin. Drug Discov. 5, 927-941 (2010).
8. Savitski, M. M. et al. Proteomics. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346, 1255784 (2014).
9. Jafari, R. et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 9, 2100-2122 (2014).
10. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87 (2013).
11. Zwier, J. M. et al. A fluorescent ligand-binding alternative using Tag-lite(R) technology. J. Biomol. Screen. 15, 1248-1259 (2010).
12. Lebakken, C. S. et al. Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform. J. Biomol. Screen. 14, 924-935 (2009).
13. Stoddart, L. A. et al. Application of BRET to monitor ligand binding to GPCRs. Nat. Methods. 12, 661-663 (2015).
14. Simon, G. M., Niphakis, M. J. & Cravatt, B. F. Determining target engagement in living systems. Nat. Chem. Biol. 9, 200-205 (2013).
15. Moreau, M. J., Morin, I. & Schaeffer, P. M. Quantitative determination of protein stability and ligand binding using a green fluorescent protein reporter system. Mol. Biosyst. 6, 1285-1292 (2010).
16. Taipale, M. et al. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat. Biotechnol. 31, 630-637 (2013).
17. Savitski, M. M. et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346, 1255784 (2014).
18. Furumai, R. et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62, 4916-4921 (2002).
19. Wang, C. et al. Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities. J. Nat. Prod. 74, 2031-2038 (2011).
20. Giang, I., Boland, E. L. & Poon, G. M. Prodrug applications for targeted cancer therapy. AAPS J. 16, 899-913 (2014).
21. Wilson, A. J., Cheng, Y. Q. & Khabele, D. Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy. J. Ovarian Res. 5, 12 (2012).
22. Wei, D. G. et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 10, e1004071 (2014).
23. Crabb, S. J. et al. Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. Biochem. Pharmacol. 76, 463-475 (2008).
24. Ito, T. et al. Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. Chem. Biol. 18, 495-507 (2011).
25. Machleidt, T. et al. NanoBRET-A novel BRET platform for the analysis of protein-protein interactions. ACS Chem. Biol. 10, 1797-1804 (2015).
26. Pfleger, K. D. & Eidne, K. A. Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nat. Methods 3, 165-174 (2006).
27. Pfleger, K. D., Seeber, R. M. & Eidne, K. A. Bioluminescence resonance energy transfer (BRET) for the real-time detection of protein-protein interactions. Nat. Protoc. 1, 337-345 (2006).
28. Dacres, H., Dumancic, M. M., Horne, I. & Trowell, S. C. Direct comparison of bioluminescence-based resonance energy transfer methods for monitoring of proteolytic cleavage. Anal. Biochem. 385, 194-202 (2009).
29. Friedman Ohana, R. et al. Deciphering the cellular targets of bioactive compounds using a chloroalkane capture tag. ACS Chem. Biol. 10, 2316-2324 (2015).
30. Griss, R. et al. Bioluminescent sensor proteins for point-of-care therapeutic drug monitoring. Nat. Chem. Biol. 10, 598-603 (2014).
31. Hall, M. P. et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem. Biol. 7, 1848-1857 (2012).
32. Bradner, J. E. et al. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6, 238-243 (2010).
33. Finnin, M. S. et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188-193 (1999).
34. Wang, D. F., Helquist, P., Wiech, N. L. & Wiest, O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J. Med. Chem. 48, 6936-6947 (2005).
35. Miller, K. M. et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat. Struct. Mol. Biol. 17, 1144-1151 (2010).
36. Yao, Y. L. & Yang, W. M. Beyond histone and deacetylase: an overview of cytoplasmic histone deacetylases and their nonhistone substrates. J. Biomed. Biotechnol. 2011, 146493 (2011).
37. Zhang, Y., Gilquin, B., Khochbin, S. & Matthias, P. Two catalytic domains are required for protein deacetylation. J. Biol. Chem. 281, 2401-2404 (2006).
38. Zou, H., Wu, Y., Navre, M. & Sang, B. C. Characterization of the two catalytic domains in histone deacetylase 6. Biochem. Biophys. Res. Commun. 341, 45-50 (2006).
39. Cheng, Y. & Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108 (1973).
40. Witt, O., Deubzer, H. E., Milde, T. & Oehme, I. HDAC family: what are the cancer relevant targets? Cancer. Lett. 277, 8-21 (2009).
41. Wang, C., Flemming, C. J. & Cheng, Y. Q. Discovery and activity profiling of thailandepsins A through F, potent histone deacetylase inhibitors, from E264. MedChemComm 3, 976-981 (2012).
42. Wilting, R. H. et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 29, 2586-2597 (2010).
43. Yamaguchi, T. et al. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev. 24, 455-469 (2010).
44. Neumann, L., von Konig, K. & Ullmann, D. HTS reporter displacement assay for fragment screening and fragment evolution toward leads with optimized binding kinetics, binding selectivity, and thermodynamic signature. Methods Enzymol. 493, 299-320 (2011).
45. Di Micco, S. et al. Structural basis for the design and synthesis of selective HDAC inhibitors. Bioorg. Med. Chem. 21, 3795-3807 (2013).
46. Fournel, M. et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer. Ther. 7, 759-768 (2008).
47. Bonfils, C. et al. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin. Cancer Res. 14, 3441-3449 (2008).
48. Schulze, J. et al. Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4. J Biomol. Screen. 20, 180-189 (2014).
49. Davis, M. I. et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051 (2011).
50. Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
51. Guenther, M. G., Barak, O. & Lazar, M. A. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol. Cell. Biol. 21, 6091-6101 (2001).
52. Couturier, C. & Deprez, B. Setting Up a bioluminescence resonance energy transfer high throughput screening assay to search for protein/protein interaction inhibitors in mammalian cells. Front. Endocrinol. 3, 100 (2012).
53. Dacres, H., Dumancic, M. M., Horne, I. & Trowell, S. C. Direct comparison of fluorescence-and bioluminescence-based resonance energy transfer methods for real-time monitoring of thrombin-catalysed proteolytic cleavage. Biosens. Bioelectron. 24, 1164-1170 (2009).
54. Lebakken, C. S., Reichling, L. J., Ellefson, J. M. & Riddle, S. M. Detection of allosteric kinase inhibitors by displacement of active site probes. J Biomol. Screen. 17, 813-821 (2012).
55. Halley, F. et al. A bioluminogenic HDAC activity assay: validation and screening. J Biomol. Screen. 16, 1227-1235 (2011).
56. Ohana, R. F. et al. HaloTag-based purification of functional human kinases from mammalian cells. Protein Expr. Purif. 76, 154-164 (2011).